Why the study?
Guidelines conflict on whether beta-blockers should be used for ventricular rate control in patients during acute HF induced by rapid AF, and systematic reviews on this issue are lacking.
Do short-acting beta-blockers (esmolol and landiolol) safely and effectively control ventricular rate and improve hemodynamics in patients with acute heart failure induced by rapid atrial fibrillation?
Do short-acting beta-blockers (esmolol and landiolol) safely and effectively control ventricular rate and improve hemodynamics in patients with acute heart failure induced by rapid atrial fibrillation?
This narrative review synthesizes evidence resolving the guideline contradiction between AF and HF management, highlighting that ultra-short-acting intravenous beta1-blockers like landiolol and esmolol can safely achieve rapid rate control and hemodynamic stabilization in acute heart failure with rapid AF when used cautiously in patients with preserved blood pressure.
Answers are grounded in this paper and cite their sources.
Short-acting beta-blockers' role in acute HF with rapid AF remains unclear; leaves open optimal strategies amid conflicting guidelines.
Rapid atrial fibrillation (rapid AF) often induces or exacerbates acute heart failure (HF). However, there is controversy regarding whether β-blockers should be used to control the ventricular rate in patients during the acute HF phase. AF management guidelines generally recommend considering the addition of β-blockers when digoxin-like drugs (such as cedilanid) fail to effectively control the ventricular rate. Nevertheless, HF guidelines clearly state that β-blockers should be used with caution during the acute decompensation phase to avoid the negative inotropic effect that may exacerbate the condition. This article systematically reviews the clinical management strategies under this guideline contradiction, including: (1) Different recommendations on ventricular rate control and the use of β-blockers in domestic and international guidelines for AF and HF; (2) A pooled analysis of relevant research evidence; (3) Application strategies of β-blockers (especially short-acting agents esmolol and landiolol) in the acute phase. We focus on discussing the latest research progress and clinical application strategies of esmolol and landiolol in HF induced by rapid AF, evaluate their effectiveness and safety. Although some studies and consensus articles have focused on the management of rapid AF complicated by HF, there is currently a lack of systematic reviews on this issue. Therefore, the writing of this review has important academic value and clinical guiding significance, providing a reference for treatment decisions in this special population.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: